These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36315391)

  • 1. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
    Gehin JE; Goll GL; Brun MK; Jani M; Bolstad N; Syversen SW
    BioDrugs; 2022 Nov; 36(6):731-748. PubMed ID: 36315391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
    Brun MK; Goll GL; Jørgensen KK; Sexton J; Gehin JE; Sandanger Ø; Olsen IC; Klaasen RA; Warren DJ; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA; Syversen SW
    J Intern Med; 2022 Sep; 292(3):477-491. PubMed ID: 35411981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
    Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
    Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.
    Chen PK; Lan JL; Chen YM; Chen HH; Chang SH; Chung CM; Rutt NH; Tan TM; Mamat RNR; Anuar ND; Blackburn JM; Chen DY
    J Immunol Res; 2021; 2021():6656121. PubMed ID: 33763493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).
    Syversen SW; Goll GL; Jørgensen KK; Olsen IC; Sandanger Ø; Gehin JE; Warren DJ; Sexton J; Mørk C; Jahnsen J; Kvien TK; Bolstad N; Haavardsholm EA
    Trials; 2020 Jan; 21(1):13. PubMed ID: 31907007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
    BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
    Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.
    Vincent FB; Morand EF; Murphy K; Mackay F; Mariette X; Marcelli C
    Ann Rheum Dis; 2013 Feb; 72(2):165-78. PubMed ID: 23178294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.
    Hiltunen J; Parmanne P; Sokka T; Lamberg T; Isomäki P; Kaipiainen-Seppänen O; Peltomaa R; Uutela T; Pirilä L; Taimen K; Kauppi MJ; Yli-Kerttula T; Tuompo R; Relas H; Kortelainen S; Paalanen K; Asikainen J; Ekman P; Santisteban A; Vidqvist KL; Tadesse K; Romu M; Borodina J; Elfving P; Valleala H; Leirisalo-Repo M; Rantalaiho V; Kautiainen H; Jokiranta TS; Eklund KK;
    Rheumatol Int; 2022 Jun; 42(6):1015-1025. PubMed ID: 34357455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
    Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
    Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease.
    Barrau M; Duprat M; Veyrard P; Tournier Q; Williet N; Marc Phelip J; Waeckel L; Cheifetz AS; Papamichael K; Roblin X; Paul S
    J Crohns Colitis; 2023 Apr; 17(4):633-643. PubMed ID: 36301958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
    Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
    Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.
    Thomas SS; Borazan N; Barroso N; Duan L; Taroumian S; Kretzmann B; Bardales R; Elashoff D; Vangala S; Furst DE
    BioDrugs; 2015 Aug; 29(4):241-58. PubMed ID: 26280210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.
    Strand V; Gonçalves J; Hickling TP; Jones HE; Marshall L; Isaacs JD
    BioDrugs; 2020 Feb; 34(1):27-37. PubMed ID: 31721107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
    Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
    Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 20. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
    Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.